Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat.
Gender differences in the incidence of cardiovascular disease have been related to plasma estrogen levels; however, the role of vascular estrogen receptor (ER) subtypes in these sex differences is less clear. We tested whether the gender differences in vascular smooth muscle (VSM) function reflect differential expression/activity of ERalpha, ERbeta and the newly-identified GPR30. Single aortic VSM cells (VSMCs) were freshly isolated from male and female Sprague-Dawley rats, and their contraction to phenylephrine (PHE, 10(-5) M), AngII (10(-7) M) and membrane-depolarization by KCl (51 mM) was measured in the absence or presence of 10(-6) M 17beta-estradiol (E2, stimulant of most ERs), PPT (ERalpha agonist), DPN (ERbeta agonist), and ICI 182,780 (an ERalpha/ERbeta antagonist with GPR30 agonistic properties). The cells were fixed and fluorescently labeled with ERalpha, ERbeta or GPR30 antibody, and the subcellular distribution of ERs was examined using digital imaging microscopy. The mRNA expression and protein amount of aortic ER subtypes was examined using RT-PCR and Western blots. PHE, AngII, and KCl caused less contraction in VSMCs of females than males. Pretreatment of VSMCs with E2 reduced PHE-, AngII- and KCl-induced contraction in both males and females. PPT caused similar inhibition of PHE-, AngII- and KCl-induced contraction as E2, suggesting a role of ERalpha. DPN mainly inhibited PHE and KCl contraction, suggesting an interaction between ERbeta and Ca(2+) channels. ICI 182,780 did not reduce aortic VSMC contraction, suggesting little role for GPR30. RT-PCR and Western blots revealed greater expression of ERalpha and ERbeta in VSMCs of females than males, but similar amounts of GPR30. The total immunofluorescence signal for ERalpha and ERbeta was greater in VSMCs of females than males, and was largely localized in the nucleus. GPR30 fluorescence was similar in VSMCs of males and females, and was mainly in the cytosol. In PPT treated cells, nuclear ERalpha signal was enhanced. DPN did not affect the distribution of ERbeta, and ICI 182,780 did not significantly increase GPR30 in the cell surface. Thus, ER subtypes demonstrate similar responsiveness to specific agonists in VSMCs of male and female rats. The reduced contraction in VSMCs of females could be due to gender-related increase in the expression of ERalpha and ERbeta.
Ma
Yukui
Y
Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston.
Qiao
Xiaoying
X
Falone
Anthony E
AE
Reslan
Ossama M
OM
Sheppard
Stephanie J
SJ
Khalil
Raouf A
RA
D000818:Animals; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005260:Female; D000077267:Fulvestrant; D036145:Ginsenosides / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000502:physiology*; D009243:NAD / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000378:metabolism; D012502:Sapogenins / Q000494:pharmacology; D012737:Sex Factors
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D036145:Ginsenosides; C520305:Gper1 protein, rat; D043562:Receptors, G-Protein-Coupled; D012502:Sapogenins; C507965:ginsenoside 20S-protopanaxatriol; D009243:NAD; D000077267:Fulvestrant; D004958:Estradiol; D011189:Potassium Chloride
Curr Med Chem Cardiovasc Hematol Agents. 2005 Oct;3(4):305-22
16250862
Artery. 1983;12(1):1-23
6431945
Am J Cardiol. 2002 Jul 3;90(1A):3F-6F
12106632
Expert Rev Cardiovasc Ther. 2007 Jul;5(4):777-89
17605655
FEBS Lett. 2008 Mar 5;582(5):635-42
18242172
Mol Cell Endocrinol. 2003 Aug 29;206(1-2):13-22
12943986
Am J Physiol. 1994 Apr;266(4 Pt 1):C975-80
8178970
J Pharmacol Exp Ther. 2005 Jun;313(3):1203-8
15722404
Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R233-49
14707008
Mol Pharmacol. 2008 Dec;74(6):1533-43
18768737
Am J Physiol. 1992 Sep;263(3 Pt 1):C714-9
1415520
Am J Physiol Cell Physiol. 2003 Dec;285(6):C1437-44
12890645
Mol Endocrinol. 2000 Oct;14(10):1649-60
11043579
Curr Med Chem. 2009;16(15):1863-87
19442151
J Physiol. 2006 Dec 15;577(Pt 3):945-55
17038424
Am J Physiol Cell Physiol. 2001 Jan;280(1):C34-45
11121374
Arteriosclerosis. 1985 Nov-Dec;5(6):668-77
4074199
Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1486-93
18832085
Atherosclerosis. 2008 Jan;196(1):49-58
17367797
Hypertension. 2007 Jun;49(6):1358-63
17452498
Circulation. 1995 Jul 1;92(1):5-8
7788916
J Pharmacol Exp Ther. 1988 Jan;244(1):19-22
3121846
Am J Physiol Cell Physiol. 2000 Apr;278(4):C834-44
10751331
J Pharmacol Exp Ther. 1988 Feb;244(2):537-42
3346836
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S99-101
11078348
Gynecol Endocrinol. 2009 Feb;25(2):82-95
19253103
Hypertension. 2004 Dec;44(6):789-95
15477384
Am J Cardiol. 1994 May 15;73(13):951-2
8184850
Eur J Pharmacol. 2002 Jun 12;445(3):247-56
12079690
Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1295-306
12531733
Hypertension. 1999 Oct;34(4 Pt 2):931-6
10523387
Clin Exp Pharmacol Physiol. 1996 Mar;23(3):256-9
8934618
Crit Rev Eukaryot Gene Expr. 1992;2(1):19-63
1543897
Circ Res. 2005 Oct 14;97(8):829-36
16151024
Peptides. 2008 Aug;29(8):1338-46
18486991
Circ Res. 2000 Nov 24;87(11):E44-52
11090554
Circ Res. 1991 Dec;69(6):1626-31
1954682
Am J Physiol. 1997 Apr;272(4 Pt 2):H1819-25
9139968
Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):1034-40
10195933
J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1):4-10
11881054
Circ Res. 2002 May 31;90(10):1087-92
12039798
J Vasc Surg. 2010 Apr;51(4):972-81
20347696
Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86
18991792
Circ Res. 1972 Mar;30(3):341-9
5060434
Am J Physiol. 1997 Nov;273(5):H2325-32
9374769
Gynecol Endocrinol. 2006 Jan;22(1):44-7
16522533
Science. 2002 Jan 18;295(5554):505-8
11799247
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):350-3
18406603
FEBS Lett. 2009 Nov 3;583(21):3448-54
19804776
Br J Pharmacol. 1991 Dec;104(4):1033-7
1810590
Endocrinology. 1999 Feb;140(2):800-4
9927308
J Am Coll Cardiol. 1992 Aug;20(2):458-9
1634686
Mol Endocrinol. 2008 Nov;22(11):2544-56
18787042
Endocrinology. 2007 Jul;148(7):3236-45
17379646
J Med Chem. 2000 Dec 28;43(26):4934-47
11150164
J Clin Invest. 1997 May 15;99(10):2429-37
9153286
Eur J Pharmacol. 1995 Dec 29;294(2-3):625-35
8750727
Circ Res. 1984 Aug;55(2):227-37
6744532
J Physiol. 1992 Sep;455:585-99
1484363
J Pharmacol Sci. 2007 Sep;105(1):74-81
17895590
Am J Physiol. 1998 Jul;275(1):H292-300
9688926
JAMA. 1991 Apr 10;265(14):1861-7
2005736
Science. 2005 Mar 11;307(5715):1625-30
15705806
Br J Pharmacol. 2003 Aug;139(7):1249-53
12890703
Science. 2005 Jun 10;308(5728):1583-7
15947175
Cell Signal. 2004 Mar;16(3):301-11
14687660